4-氰基-2-甲基苯甲酸乙酯 | 220389-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-2-甲基苯甲酸乙酯
• 英文名称: ethyl 4-cyano-2-methylbenzoate
• 英文别名: 4-cyano-2-methyl-benzoic acid ethyl ester
• CAS: 220389-17-3
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: SPCFCNSKNBMRGO-UHFFFAOYSA-N

物化性质

• 沸点：
  316.5±30.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  4-氰基-2-甲基苯甲酸乙酯 生成 4-(imino-methoxycarbonylaminomethyl)-2-methyl-benzoic acid ethyl ester
  参考文献：
  名称：

  METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS

  摘要：

  本发明涉及一种识别作为胰岛素敏感剂的化合物的方法。该方法可以包括在两种胰岛素敏感性测定中筛选试验化合物。该方法可以确定用于治疗由胰岛素抵抗引起的葡萄糖摄取紊乱的先导化合物。该发明还包括治疗胰岛素抵抗及相关疾病的方法。

  公开号：

  US20090318465A1
• 作为产物：
  描述：

  4-溴-2-甲基苯甲酸乙酯 生成 4-氰基-2-甲基苯甲酸乙酯
  参考文献：
  名称：

  N-acylamino acid amide compounds and intermediates for preparation thereof

  摘要：

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。

  公开号：

  US06265418B1

文献信息

• Fibrinogen receptor antagonists and their use
  申请人：Piramal Life Sciences Limited

  公开号：US07759387B2

  公开（公告）日：2010-07-20

  This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

  这项发明涉及一般式(I)的新型融合双环化合物： 其中符号在此定义，包括含有这些化合物的药物组合物、制备这些化合物的方法，以及使用这些化合物的方法，单独或与其他治疗剂联合使用。这些化合物是血小板糖蛋白IIb/IIIa纤维蛋白原受体复合物的拮抗剂，因此对于抑制血小板聚集以及治疗血栓性疾病和其他疾病是有用的。
• Inhibitors of cyclin-dependent kinases and their use
  申请人：——

  公开号：US20040106581A1

  公开（公告）日：2004-06-03

  The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.

  本发明涉及一种新型化合物，用于抑制细胞周期蛋白依赖性激酶，尤其是公式（Ia）的香豆素衍生物，其中R1、R2、R3、R4、R5、R6、R7和A的含义如权利要求中所示。本发明还涉及制备公式（Ia）化合物的方法，抑制细胞周期蛋白依赖性激酶和细胞增殖的方法，使用公式（Ia）化合物治疗和预防由于细胞周期蛋白依赖性激酶抑制而可以治疗或预防的疾病，如癌症，使用公式（Ia）化合物制备用于治疗此类疾病的药物。本发明还涉及含有公式（Ia）化合物的组合物，单独或与另一活性剂结合，与惰性载体混合或以其他方式结合，特别是含有公式（Ia）化合物的药物组合物，单独或与另一活性剂结合，与药用可接受载体物质和辅助物质一起使用的制剂。
• INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE
  申请人：Lal Bansi

  公开号：US20070015802A1

  公开（公告）日：2007-01-18

  The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ic) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ic) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ic) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ic) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ic) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.

  本发明涉及一种新型化合物，用于抑制细胞周期蛋白依赖性激酶，特别是公式(Ic)的香豆素衍生物，其中R1、R2、R3、R4、R5、R6、R7和A的含义如权利要求所示。本发明还涉及制备公式(Ia)化合物的方法，抑制细胞周期蛋白依赖性激酶和抑制细胞增殖的方法，以及使用公式(Ic)化合物在治疗和预防细胞周期蛋白依赖性激酶抑制剂可治疗或预防的疾病，如癌症，以及使用公式(Ic)化合物制备应用于这些疾病的药物。本发明还涉及含有公式(Ic)化合物的组合物，单独或与另一种活性剂联合使用，与惰性载体混合或以其他方式与惰性载体相结合，特别是含有公式(Ic)化合物的药物组合物，单独或与另一种活性剂联合使用，以及与药用载体物质和辅助物质相结合。
• FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE
  申请人：Lal Bansi

  公开号：US20100256161A1

  公开（公告）日：2010-10-07

  This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

  本发明涉及一种新型的融合双环化合物，其一般式为(I)：其中符号的定义如下，以及包含该化合物的制药组合物，制备该化合物的方法以及使用该化合物的方法，单独或与其他治疗剂联合使用。该化合物是血小板糖蛋白IIb/IIIa纤维蛋白原受体复合物的拮抗剂，因此对于抑制血小板聚集以及治疗血栓性疾病和其他疾病具有用处。
• Inhibitors of Cyclin Dependent Kinases and Their Use
  申请人：Lal Bansi

  公开号：US20110136873A1

  公开（公告）日：2011-06-09

  The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.

  本发明涉及新型化合物，用于抑制细胞周期蛋白依赖性激酶，更具体地说，涉及公式(Ia)的香豆酮衍生物，其中R1、R2、R3、R4、R5、R6、R7和A具有所述权利要求中指示的含义。本发明还涉及制备公式(Ia)化合物的方法，抑制细胞周期蛋白依赖性激酶和抑制细胞增殖的方法，以及使用公式(Ia)化合物治疗和预防通过抑制细胞周期蛋白依赖性激酶治疗或预防的疾病，如癌症，使用公式(Ia)化合物制备应用于此类疾病的药物。本发明还涉及含有公式(Ia)化合物的组合物，单独或与另一活性剂混合，与惰性载体混合或以其他方式与惰性载体相关联，特别是含有公式(Ia)化合物的制药组合物，单独或与另一活性剂混合，以及与药物可接受的载体物质和辅助物质一起使用。